研究单位：[1]Pfizer[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China,650032[3]Anhui Provincial Hospital Hefei,Anhui,China,230001[4]The First Affiliated Hospital of Anhui Medical University/Rheumatology Department Hefei,Anhui,China,230022[5]Peking University First Hospital Beijing,Beijing,China,100034[6]Peking Union Medical College Hospital Beijing,Beijing,China,100730[7]The First Affiliated Hospital of Army Medical University,PLA Chongqing,Chongqing,China,400038[8]The First Affiliated Hospital of Xiamen University Xiamen,Fujian,China,361003[9]The First Affiliated Hospital,Sun Yat-sen University Guangzhou,Guangdong,China,510080[10]Guangzhou First People's Hospital Guangzhou,Guangdong,China,510180
研究目的：
This is a 6 month study investigating the effectiveness and safety of tofacitinib in treating signs and symptoms and improving physical function in Chinese patients with active psoriatic arthritis and had inadequate response to a conventional synthetic disease modifying anti-rheumatic drug. This is a China alone study.
